SENS-218
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inner Ear Diseases
Conditions
Inner Ear Diseases
Trial Timeline
Feb 1, 2016 → Mar 1, 2016
NCT ID
NCT02772796About SENS-218
SENS-218 is a phase 1 stage product being developed by Sensorion for Inner Ear Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT02772796. Target conditions include Inner Ear Diseases.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02772796 | Phase 1 | Completed |
Competing Products
3 competing products in Inner Ear Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2) | Swedish Orphan Biovitrum | Phase 2 | 51 |
| gevokizumab | XOMA | Phase 2 | 44 |
| SENS-401 + Placebo | Sensorion | Phase 1 | 25 |